Local production of tumor necrosis factor alpha, interleukin 1, and interleukin 6 in meningococcal meningitis. Relation to the inflammatory response

We examined the cerebrospinal fluid (CF) taken on admission from 60 patients with infections caused by Neisseria meningitidis for presence of TNF-alpha, IL-1, and IL-6. TNF-alpha was detected in CF in 55 and 19% (p = 0.03), IL-1 in 50 and 15% (p = 0.05), and IL-6 in 98 and 100% of patients with meningitis and septic shock/bacteremia, respectively. The median IL-6 concentration in CF in patients with meningitis was 154 ng/ml, and in patients with septic shock/bacteremia it was 42 ng/ml (p = 0.001). The level of LPS in CF correlated with the level of TNF-alpha (r = 0.91, p less than 0.001), but not with the level of IL-1 and IL-6. CF levels of TNF-alpha, IL-1, and IL-6 correlated with each other (r = 0.34-0.54, p less than 0.01), with the protein concentration (r = 0.34- 0.62, p less than 0.01) and inversely with the CF/blood glucose ratio (r = -0.34 to -0.67, p less than 0.01). Only the Il-6 level correlated with the leukocyte count (r = 0.37, p less than 0.01). In rabbits TNF- alpha, IL-1, and IL-6 activities sequentially appeared in CF within 3 h of injection of meningococcal LPS or viable meningococci, whereas the main infiltration of granulocytes started after 4 h. TNF-alpha was detected in serum at concentrations less than 1/100 of those in CF after administration of LPS into the subarachnoid space, and conversely, TNF-alpha was detected in CF at concentrations 1/100 of those in serum after intravenous injection of LPS. The results demonstrate that TNF-alpha, IL-1, and IL-6 are sequentially produced in the initial phase of the local inflammatory response caused by meningococci, and that the subarachnoid space and systemic circulation are separate compartments with respect to production of TNF-alpha, IL- 1, and IL-6.

[1]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .

[2]  P. Brandtzaeg,et al.  Plasma endotoxin as a predictor of multiple organ failure and death in systemic meningococcal disease. , 1989, The Journal of infectious diseases.

[3]  C. Dinarello,et al.  Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. , 1984, Journal of immunology.

[4]  R. Cotran,et al.  Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. , 1985, The Journal of clinical investigation.

[5]  W. Fiers,et al.  Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon gamma , 1989, The Journal of experimental medicine.

[6]  R. Ulevitch,et al.  Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. , 1988, The Journal of clinical investigation.

[7]  L. Aarden,et al.  Molecular cloning and expression of hybridoma growth factor in Escherichia coli. , 1987, Journal of immunology.

[8]  N. Ruddle Activation of human polymorphonuclear neutrophil functions by interferon-gamma and tumor necrosis factors. , 1986, Journal of immunology.

[9]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[10]  T. Taniguchi,et al.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin , 1986, Nature.

[11]  R. Coffman,et al.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. , 1986, Journal of immunology.

[12]  T. Mosmann Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[13]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[14]  E. Tuomanen Partner drugs: a new outlook for bacterial meningitis. , 1988, Annals of internal medicine.

[15]  T. Ikejima,et al.  Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. , 1988, The Journal of clinical investigation.

[16]  E. Girardin,et al.  Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. , 1988, The New England journal of medicine.

[17]  T. Espevik,et al.  Interleukin-6 in synovial fluid from patients with arthritis. , 1989, Clinical immunology and immunopathology.

[18]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[19]  J. Vilček,et al.  Tumor necrosis factor and interleukin 1: cytokines with multiple overlapping biological activities. , 1987, Laboratory investigation; a journal of technical methods and pathology.

[20]  A. Mantovani,et al.  Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. , 1987, Journal of immunology.

[21]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[22]  A. Waage,et al.  Interleukin 1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice , 1988, The Journal of experimental medicine.